Premium
Pregnancy Outcomes after Maternal Exposure to Fluconazole
Author(s) -
Jick Susan S.
Publication year - 1999
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.19.3.221.30919
Subject(s) - fluconazole , pregnancy , medicine , azole , first trimester , obstetrics , gestation , antifungal , dermatology , genetics , biology
We evaluated pregnancy outcomes in 234 women exposed to fluconazole, 492 exposed to a topically administered azole preparation, 88 exposed to an oral azole preparation other than fluconazole, and 1629 not exposed to any of these agents during the first trimester of pregnancy. Relative risks of having a baby with a congenital disorder for women exposed to fluconazole, oral azoles, and topical azoles in the first trimester of pregnancy compared with those who were unexposed were 1.1 (95% CI 0.4–3.3), 2.1 (95% CI 0.7–6.8), and 0.6 (95% CI 0.2–1.6), respectively. These results provide reassurance that fluconazole exposure in the first trimester of pregnancy does not materially increase the risk of congenital disorders in infants.